Clinical advisory Board
Prof. Pierre Van Damme, MD, PhD - University of Antwerp, Belgium.
Pierre van Damme heads the Vaccine and Infectious Disease Institute (Antwerp University) since 2007. A highly respected vaccinologist, he has conducted more than 250 clinical trials over the last 25 years and is editor or referee on 16 peer-reviewed journals in vaccines and infectious diseases. He is policy advisor to WHO, the EU and the ECDC and sits on a number of public health advisory committees. Dr Van Damme is one the the lead clinical investigator of GTL001 (ProCervix) clinical trials.
Prof. Diane Harper, MD, MPH, MS - University of Louisville, United States.
Diane Harper is the Gradie and Mary Rowntree Endowed Chair and professor of family and geriatric medicine, obstetrics and gynecology, epidemiology and population health, health promotion and behavioral sciences and bioengineering. She is an ad hoc advisor to WHO on HPV vaccines and has served as principal investigator in several large HPV vaccine clinical trials with Cervarix® and Gardasil® (GSK and Merck, respectively). Dr Harper is a key opinion leader, researcher and clinician in HPV disease prevention and vaccination and has published over 100 scientific papers in her field. Dr Harper is the lead investigator of Genticel's phase 1 clinical trial in the United States.
Prof. Emeritus Chris Meijer, MD - Vrije Universiteit Amsterdam Medical Centre, Netherlands.
Chris Meijer is a key opinion leader in epidemiology, detection and diagnosis of pathologies caused by HPV and is closely involved in the working groups advising European and National Public Health Authorities on guidelines for diagnosis and prognosis of HPV-related diseases.
Prof. Anne-Barbara Moscicki, MD - University of California, San Francisco, United States.
Anna-Barbara Moscicki is Professor of Paediatrics and is Principal Investigator of a 27-year study of the natural history of HPV in young women. She is also a renowned specialist in clinical immune response to HPV infection and vaccination.
Prof. Margaret Stanley, PhD - University of Cambridge, United Kingdom.
Margaret Stanley is Professor of Epithelial Biology at the University of Cambridge, Fellow of the Academy of Medical Sciences, and Honorary Fellow of the Royal College of Obstetricians and Gynaecologists. She is also a renowned specialist in clinical immune response to HPV infection and vaccination.
Prof. Xavier Bosch, MD – MPH - Catalan Institute of Oncology in Barcelona, Spain.
Xavier Bosch is Chief of the Cancer Epidemiology and Registration Program and Chief of International Affairs at the Catalan Institute of Oncology in Barcelona, Spain. Dr Bosch's interests focus on viral-related cancers. He is a specialist in cervical cancer epidemiology and the use of HPV technologies for screening and vaccination. He has published over 450 scientific papers on HPV-related topics and more than 10 major international reviews.